Table 2

Peripheral blood lymphocyte quantification
CD4:CD8 ratio CD3CD4 (%) CD3CD4 106cells/L CD3CD8 (%) CD3CD8 106cells/L CD16CD56 (%) CD16CD56 106cells/L
no-fatigue controls (n = 32) 2.43 (0.97) 51.1 (8.2) 990 (376) 22.9 (5.5) 440 (198) 11.7 (6.7) 210 (99)
PI-CFS/ICF (n=24) 2.05 (0.76) 50.5 (7.0) 939 (366) 27.0 (7.0) 497 (207) 7.5 (3.5)** 130 (54)**
  PI-CFS (n = 19) 2.01 (0.77) 50.3 (6.9) 912 (296) 27.5 (7.0)* 497 (200) 8.0 (3.6)* 138 (55)**
Fatigue other cause (n=12) 2.37 (1.14) 51.9 (8.1) 1132 (543) 26.1 (10.4) 635 (531) 8.7 (4.6) 186 (139)
Fatigue recovered (n=12) 1.80 (0.82)* 46.1 (10.3) 834 (318) 28.8 (9.1)* 545 (225) 10.6 (9.0) 203 (188)
no-FGID (n=26) 2.74 (1.06) 53.3 (8.6) 1008 (363) 21.1 (5.4) 394 (167) 11.3 (7.1) 192 (80)
All FGID (n=54) 1.96 (0.75)** 48.9 (7.7)* 958 (415) 27.6 (7.6)*** 555 (311)** 9.1 (5.6) 176 (129)
 PI-FGID (n=45) 2.00 (0.78)** 49.2 (7.9)* 949 (418) 27.1 (7.35)** 537 (313)* 8.8 (5.4) 169 (122)
  PI-IBS (n=23) 1.97 (0.91)** 49.5 (8.8) 988 (463) 28.2 (7.1)** 592 (376)* 8.1 (5.0)* 157 (111)
no-FGID/no-fatigue controls (n=23) 2.65 (1.05) 52.4 (8.8) 974 (380) 21.5 (5.5) 389 (171) 11.8 (7.6) 194 (86)
FGID&CFS/ICF(n=23) 2.01 (0.75)* 50.2 (7.0) 923 (366) 27.3 (6.9)** 500 (211) 7.4 (3.5)** 127 (53)*
FGID, no fatigue (n=21) 1.82 (0.65)** 46.9 (8.5)* 924 (356) 27.9 (7.3)** 548 (214)** 11.0 (7.0) 223 (156)
Fatigue other cause w/wo FGID (n=12) 2.37 (1.14) 51.9 (8.1) 1133 (543) 26.1 (10.4) 635 (531) 8.7 (4.6) 186 (140)

* p < 0.05 level compared to the control group (in italics) in each categorization.

** Significant at p<0.01 level compared to the control group (in italics) in its categorization.

*** Significant at p<0.001 level compared to the control group (in italics) in its categorization.

CD4:CD8 T-cells ratio, CD4 and CD8 T-cell subsets, CD16CD56 natural killer cells percentages and concentrations by analysis categorizations and relevant subgroups. All values are given as mean (SD). Data for the subgroups of PI-CFS, PI-FGID and PI-IBS are also given (indented).

Hanevik et al.

Hanevik et al. BMC Infectious Diseases 2012 12:258   doi:10.1186/1471-2334-12-258

Open Data